Table 6.
Patient characteristics in [177Lu]Lu-DOTA-TATE (ERASMUS) before and after matching to RADIANT-3.a
| Patient characteristic | ERASMUS (pre-match) |
ERASMUS (post-match everolimus) |
RADIANT-3 |
ERASMUS (post-match BSC) |
RADIANT-3 |
|
|---|---|---|---|---|---|---|
| [177Lu]Lu-DOTA-TATE | [177Lu]Lu-DOTA-TATE | Everolimus | [177Lu]Lu-DOTA-TATE | BSC | ||
| N | N | 62 | 62 | 207 | 62 | 203 |
| Effective sample size: | 22 | 18 | ||||
| Age | Mean (median) | 58 | 58 | NA (58) | 57 | NA (57) |
| ECOG performance status | 0 | 77% | 67% | 67% | 66% | 66% |
| 1 | 23% | 33% | 33% | 34% | 34% | |
| Previous radiotherapy | Yes | 3% | 23% | 23% | 20% | 20% |
| No | 97% | 77% | 77% | 80% | 80% | |
| Previous chemotherapy | Yes | 13% | 50% | 50% | 50% | 50% |
| No | 87% | 50% | 50% | 50% | 50% | |
| Sex | Male | 45% | 58% | 49% | 52% | 58% |
| Female | 55% | 42% | 51% | 48% | 42% | |
| Previous surgery | Yes | 45% | 40% | 88% | 34% | 88% |
| No | 55% | 60% | 12% | 66% | 12% | |
| Time from initial diagnosis ≤18 m | Yes | 58% | 58% | 43% | 58% | 37% |
| No | 42% | 42% | 57% | 42% | 63% | |
| Weights | Mean | 1.00 | 1.00 | |||
| Range | (0.39–12.23) | (0.31–11.22) |
a
A histogram describing the full distribution of weights is provided in the data supplement.